Harnessing Nature’s Most Powerful Repertoire Generating System for use in T-cell Therapies: Fully Human TCRs and Fully Human Antibodies Specific for MHC/peptide Complexes, and now a new proprietary scaffold, single variable domain-TCRs.
Innovative Targeting Solutions (ITS) has taken nature’s most powerful diversity generating system, V(D)J recombination, and has created a breakthrough protein engineering platform, the HuTARG™ technology, for the discovery and affinity maturation of a variety of different biologic scaffolds. ITS has previously exploited V(D)J recombination to make first-in-class fully human antibodies and HCAbs (heavy chain only antibodies) to GPCRs. The company has also applied its HuTARG™ technology to isolate rare antibodies with T-cell receptor (TCR) like properties (T-Mabs) that recognize specific MHC/peptide complexes. ITS has generated fully human T-Mabs to two different MHC/peptide complexes: anti-ESO peptide/MHC complex and an anti-HIV peptide/MHC complex. ITS has also applied the HuTARG™ technology for the generation of fully human TCRs.
Innovative Targeting Solutions now introduces a novel first-in-class scaffold for T-cell based therapies; single variable domain-TCRs (svd-TCRs). ITS has demonstrated that the TCR beta chain, in the absence of the TCR alpha chain, retains the intrinsic ability to bind to MHC/peptide complexes. A svd-TCR, as a single domain, overcomes a number of historical challenges with using a soluble TCR because it can be formatted easily as a fusion protein or engineered as a chimeric antigen receptor. The single molecule also overcomes challenges of associating the two TCR chains which have previously required extensive engineering.
The HuTARG™ platform has successfully tackled some of the most challenging target classes including GPCRs and ion channels and now this revolutionary protein engineering technology also enables Innovative Targeting Solutions to utilize multiple scaffolds to specifically target MHC/peptide complexes. We believe the HuTARG™ platform is without a doubt the most versatile and powerful protein engineering tool developed to date and will allow Innovative Targeting Solutions Inc. and its partners to generate medicines not possible with other technologies.
Innovative Targeting Solutions Inc.